Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...

Blood glucose giant Dexcom has used CES 2024 to announce a new continuous glucose monitor (CGM) designed specifically for Type 2 diabetics who don’t use insulin – Dexcom Stelo. The Stelo still ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now available ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...

Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...

DexCom Inc. DXCM recently announced the availability of Stelo, the first over-the-counter (OTC) continuous glucose monitoring (CGM) biosensor in the United States. The biosensor is available for ...